Industry News
Biotechnology Industry News

The German pharma giant has found…
The German pharma giant has found a new pipeline leader in David Weinreich, M.D., who is joining the company as global head of R&D and chief medical officer for its healthcare unit. Weinreich, who will
The Food and Drug Administration…
The Food and Drug Administration today announced a plan to publicly release complete response letters at the same time they are issued to sponsoring companies, part of what the agency calls a push toward “radical
Nine months after closing a $450…
Nine months after closing a $450 million fundraise, Atlas Venture is back with another biotech financing vehicle, raising $400 million this time.
AC Immune is reducing its…
AC Immune is reducing its workforce by around 30% and narrowing its pipeline to extend its cash runway by about six months.
Enveda has closed its second $150…
Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding beyond $500 million, positions the biotech to advance a crop of programs into the
A phase 3 trial of Sanofi’s…
A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% in Paris.
An interim analysis reported in…
An interim analysis reported in June showed that Amgen's Zai Labs-partnered bemarituzumab made improvements in overall survival, but the final analysis tells a different story.
Gilead Sciences’ Kite Pharma has…
Gilead Sciences' Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on off-the-shelf cell therapies that was valued at more than $2.3 billion.
After becoming the first group to…
After becoming the first group to therapeutically edit human RNA in October 2024, Wave Life Sciences has released more data from an ongoing alpha-1 antitrypsin deficiency clinical trial—and investors appear less enthused this time around.
The FDA has outlined a new review…
The FDA has outlined a new review process for drugs and biologics designed to treat ultra-rare genetic diseases that would allow a single-arm trial, plus other supportive data, to serve as pivotal evidence.
Treeline Biosciences has surfaced…
Treeline Biosciences has surfaced from secrecy to reveal the harvesting of a $200 million series A extension and the picking of some ripe clinical programs. The extra cash brings the Massachusetts-based oncology outfit’s total funding
Valneva has reported phase 2 data…
Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking off another task for a prospect that could reach regulatory review next year.
Novartis has returned to Argo…
Novartis has returned to Argo Biopharmaceutical with $160 million in upfront cash to explore various cardiovascular meds in the Chinese biotech’s siRNA pipeline.
After throwing down $70 million…
After throwing down $70 million upfront to partner on Black Diamond Therapeutics’ solid tumor candidate earlier this year, Servier is pulling out its checkbook to ink yet another oncology licensing deal.
Boston-based Radiance Biopharma is…
Boston-based Radiance Biopharma is doling out $15 million in cash and offering more than $1 billion in milestones for licensing rights to a bispecific antibody-drug conjugate from a Chinese drug developer.
Cytokinetics spent Labor Day…
Cytokinetics spent Labor Day weekend in Spain, sharing a big phase 3 win for its lead cardio candidate at the European Society of Cardiology Congress in Madrid. A daily pill of small molecule aficamten improved
In the next milestone in Editas’…
In the next milestone in Editas' strategic pivot, the company revealed its new lead program as a possible one-time treatment for high cholesterol.
Amgen is putting down $600 million…
Amgen is putting down $600 million to build a new R&D site in California, a move the Big Pharma says will create hundreds of U.S. jobs.
Zenas BioPharma has secured up to…
Zenas BioPharma has secured up to $300 million from Royalty Pharma in return for royalties on sales of lead autoimmune candidate obexelimab. The cash is intended to help Zenas get its star asset across the
Vertex Pharmaceuticals is offering…
Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multi-target drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.

